@article{APC5051,
author = {Imani Bijou and Jin Wang},
title = {Evolving trends in pancreatic cancer therapeutic development},
journal = {Annals of Pancreatic Cancer},
volume = {2},
number = {0},
year = {2019},
keywords = {},
abstract = {Despite advances in translational research, the overall 5-year survival for pancreatic cancer remains dismal and with rising incidence pancreatic cancer is predicted to be the second leading cause of cancer death for many developed countries. Surgical intervention followed by cytotoxic chemotherapy are currently the best options for treatment, but disease recurrence is very common. Efforts to develop new therapeutic agents and delivery systems are necessary to achieve better clinical efficacy with less toxicity. Promising prospects are arising with new preclinical and clinical therapeutic strategies using small molecule targeted therapies, RNAi, stromal therapies, and immunotherapies. With a better understanding of the biology to aid target selection and discovery of biomarkers to aid precision medicine, better opportunities will evolve to shape the therapeutic landscape, enhance patient quality of life and increase overall survival.},
issn = {2616-2741}, url = {https://apc.amegroups.org/article/view/5051}
}